Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation methods of parecoxib sodium and intermediate thereof

A technique for parecoxib sodium and intermediates, which is applied in the field of preparation of parecoxib sodium and its intermediates, can solve the problems of unsuitability for industrial production, low reaction yield, high production cost, etc., and achieve low cost and high purity High, responsive and easy post-processing effects

Inactive Publication Date: 2017-05-17
SHANGHAI BOCIMED PHARMA CO LTD
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] The technical problem to be solved by the present invention is to provide a Parecoxib sodium intermediate in order to overcome defects such as high impurity content, low reaction yield, high production cost and unsuitability for industrialized production in the prior art. Preparation method of recoxib sodium and its intermediate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation methods of parecoxib sodium and intermediate thereof
  • Preparation methods of parecoxib sodium and intermediate thereof
  • Preparation methods of parecoxib sodium and intermediate thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Embodiment 1: the preparation method of parecoxib sodium intermediate I

[0039]

[0040] The raw material valdecoxib III (5.0 g) was added to propionic anhydride (18.6 g), and stirred to dissolve. Add sulfamic acid (0.15g), heat up to 50-60°C, and react for about 3 hours. TLC monitors that the reaction is complete, cools down to about 0°C, and keeps stirring for about 1 hour. Filter, rinse the filter cake with methyl tert-butyl ether (10ml) and place it in a vacuum oven at -0.08MPa~-0.1MPa, and dry it in vacuum at 50°C for 8-12 hours to obtain 4.77g of the intermediate of parecoxib sodium 1, yield 81%. The HPLC purity is 99.91%, the maximum impurity is 0.06%, and the raw material valdecoxib III is <0.02%.

Embodiment 2

[0041] Embodiment 2: the preparation method of parecoxib sodium intermediate I

[0042] The raw material valdecoxib III (10.0 kg) was added to propionic anhydride (37.2 kg), stirred and dissolved. Add sulfamic acid (0.31kg), heat up to 50-60°C, and react for about 4 hours. TLC monitors that the reaction is complete, cools down to about 0°C, and keeps stirring for about 1 hour. After centrifugation, the filter cake was rinsed with methyl tert-butyl ether (20L) and placed in a vacuum oven at -0.08MPa~-0.1MPa, and dried at 50°C for 8-12 hours to obtain the parecoxib sodium intermediate (I) 9.31kg, yield 79.2%. The HPLC purity is 99.92%, the maximum single impurity is 0.05%, and the raw material valdecoxib III is <0.02%.

Embodiment 3

[0043] Embodiment 3: the preparation method of parecoxib sodium intermediate I

[0044] The raw material valdecoxib III (5.0 g) was added to propionic anhydride (18.6 g), and stirred to dissolve. Add methanesulfonic acid (0.15 g), heat up to 50-60° C., and react for about 3 hours. TLC monitors that the reaction is complete, cools down to about 0°C, and keeps stirring for about 1 hour. Filtrate, rinse the filter cake with methyl tert-butyl ether (10ml) and place it in a vacuum oven at -0.08MPa~-0.1MPa, and dry it in vacuum at 50°C for 8-12 hours to obtain 4.80g of parecoxib sodium intermediate 1, yield 81.5%. The HPLC purity is 99.90%, the maximum impurity is 0.07%, and the raw material valdecoxib III is <0.02%.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses preparation methods of parecoxib sodium and intermediate thereof. The invention provides a preparation method of a parecoxib sodium intermediate I. The preparation method of the parecoxib sodium intermediate I comprises the following step: in the presence of a catalyst, performing condensation reaction on valdecoxib III and propionic anhydride to obtain the parecoxib sodium intermediate I, wherein the catalyst is one or more of benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid and sulfamic acid. The preparation method is simple in reaction and post-treating operation, high in yield and low in cost; the purity of the prepared intermediate product is high and can reach 99.80% or above, and the content of specific impurity valdecoxib reaches 0.02% or below and can meet the standard of an original researching manufacturer; therefore, the preparation method is suitable for industrial production. The purity of parecoxib sodium prepared from the parecoxib sodium intermediate I prepared by the preparation method provided by the invention can reach 99.80% or above and the content of the specific impurity valdecoxib reaches 0.01% or below and is higher than the standard of the original researching manufacturer.

Description

technical field [0001] The invention relates to a preparation method of parecoxib sodium and an intermediate thereof. Background technique [0002] Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to treat inflammation and ailments, for example in arthritis and headaches. Such drugs are effective, but their long-term use is limited by gastrointestinal side effects including dyspepsia and abdominal pain and, in severe cases, gastric or duodenal perforation and / or bleeding, by combining the therapeutic efficacy of traditional NSAIDs Along with a vastly improved gastrointestinal safety profile, the development of selective COX-2 inhibitory drugs has revolutionized the treatment of inflammation and pain. Cyclooxygenase (COX) inhibition is believed to be at least the primary mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) exert their characteristic anti-inflammatory, antipyretic and analgesic effects through inhibition of prostaglandin synthesis. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D261/08
CPCC07D261/08
Inventor 应述欢皮红军陈健王刚乔岩河
Owner SHANGHAI BOCIMED PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com